Latest news

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel…

Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

GenePOC obtains FDA clearance for its GenePOC™ Carba test in the US

Debiopharm awarded $2.1 million from CARB-X in the fight against a highly resistant nosocomial-pneumonia causing superbug

GenePOC, a subsidiary of Debiopharm Group, reaches an agreement with Meridian Bioscience for the acquisition of their molecular diagnostics business

GenePOC obtains CE marked for its GenePOCTM Carba test

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…